<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The results of our previous experimental and clinical studies led us to the hypothesis that, in the pathogenesis of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, subarachnoid focal <z:hpo ids='HP_0001941'>acidosis</z:hpo> resulting from anaerobic changes of subarachnoid clots may be a factor upsetting the balanced synthesis of both <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> and <z:chebi fb="0" ids="15552">prostaglandin I2</z:chebi> from <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> endoperoxides on the inner surface of cerebral arteries </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, there is a higher concentration of <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi>, a <z:chebi fb="0" ids="26347">prostanoid</z:chebi> that causes arterial contraction and platelet aggregation </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the administration of trapidil, an <z:chebi fb="68" ids="48706">antagonist</z:chebi> and selective synthesis inhibitor of <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi>, in a series of 20 cases for the prevention of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> after aneurysmal rupture </plain></SENT>
<SENT sid="3" pm="."><plain>Vasospasm was demonstrated by angiography in 9 of these cases, but only 2 of the 9 showed mild signs of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 20 patients, 15 were discharged from the hospital as cured and 3 had a neurological deficit at discharge </plain></SENT>
<SENT sid="5" pm="."><plain>Our findings suggest the significance in symptomatic vasospasm of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation by platelet aggregation and the effectiveness of trapidil as a preventive </plain></SENT>
</text></document>